Former Daewoong Pharmaceutical Executives Minkeun Jo and Heesun Kim as Co-CEOs: “Aiming to Realize Biotransformation”
[Medical Newspaper · Ilgan Bosa] BXPLANT, which provides customized consulting services from identifying promising startups to R&D consulting, clinical trials, business development, and investment attraction, has been established.
Co-CEOs Minkeun Jo and Heesun Kim (from left), both former executives at Daewoong Pharmaceutical, announced that they established BXPLANT in January with the ambition to plan and realize a major transformation toward the bio industry.
BXPLANT provides total clinical development services across the full cycle of new drug development, including R&D strategy formulation in the bio healthcare sector, preclinical and clinical consulting, licensing and registration, and clinical trials.
The company also operates as a scalerator business that accelerates the growth of bio healthcare startups. It identifies promising companies to support their growth and operates follow-up support programs including fund formation and investment execution, as well as global expansion.
Additionally, by interconnecting the full R&D cycle with consortium companies, BXPLANT provides open innovation opportunities to startups that face networking limitations.
Co-CEO Minkeun Jo stated, “The bio industry is our future. Economists also identify bio as a key industry to prepare for the new normal era of low growth, high unemployment, and aging society,” adding, “In the coming future, as bio technology converges with ICT, NT, AI, and other industries overall, the bio economy era will arrive.”
CEO Jo further revealed, “As a Science to Business platform company, BXPLANT plans to lead the bio economy era together with more bio companies.”
Meanwhile, Co-CEO Minkeun Jo is a business expert in the pharmaceutical and bio field with a Master’s in Economics and Ph.D. in Business Administration, having served as Business Unit Director of Daewoong Pharmaceutical Consumer Healthcare Division and Head of Management Planning at Woojung BIO. Co-CEO Heesun Kim is a new drug development expert with a Master’s in Pharmacy and Ph.D. in Clinical Trial Design, having served as Clinical Development Director at NextBio Science, Director of Clinical/Regulatory Affairs at Inventage Lab, and Head of Clinical Development Center at Daewoong Pharmaceutical.
source : Scalerator & CDRO Specialist BXPLANT Established, Jeong-il Kim, Medical Newspaper Ilgan Bosa, 2024.02.26., http://www.bosa.co.kr/news/articleView.html?idxno=2217337
